Introduction
The precision of radiotherapy for prostate cancer has been improving, and intensity-How to cite this paper: Tanaka, O., Komeda, H., Iida, T., Tamaki, M., Seike, K., Kato, D., Yokoyama, T., Hirose, S., Kawaguchi, D. and [3], because the treatment must often be repeated and markers capable of being depicted on magnetic resonance imaging (MRI) are necessary. Herein, we report our findings regarding the utility of a 0.5%-iron-containing fiducial marker (Gold Anchor™ [GA]; Naslund Medical AB, Huddinge, Sweden) versus a commonly used linear fiducial marker (VISICOIL™ [VIS]; RadioMed Corporation, Bartlett, TN, USA) in five patients at our hospital.
Materials and Methods
From April to May 2016, five patients participated in this study. All of the patients provided written informed consent. The fiducial marker was placed by urologists via the transperineal method under local anesthesia. The VIS was placed on one side of the prostate, and the GA was placed on the opposite site.
The GA was 0.28 mm in diameter and 10 mm in length and had a winding, zigzagshape that could be bent to make the marker spherically shaped ( Figure 1 ). The VIS was 0.35 mm in diameter and 10 mm in length and was linear, as is most common. The Gas was inserted using 22 G needles, and the VISs were inserted using 19 G needles (the thinnest needle available for the VIS in Japan). Patients on anticoagulants were excluded from the study. Three weeks after the insertion of the GA and VIS, computed tomography (CT) and MRI were performed. MRI was performed with 3-mm section thickness, no intersection gaps, and a 16-cm field of view using a cardiac coil. The sequence was as follows: T1-WI, T2-WI, T2*2D-WI, T2*3D-WI, and contrast-enhanced T1-WI. The details of the modalities are described above.
Image Acquisition
We evaluated the images obtained using T2-WI, T2*2D-WI, and T2*3D-WI among the five sequences because these showed the best visualization. We primarily examined the degree of artifacts on CT and marker visualization on MRI.
The radiotherapy instrument used was a Novalis Tx system (Varian Medical Systems, Inc., Palo Alto, CA, USA). Before we began the present study, the 0.35 mm × 10 mm and 0.5 mm × 10 mm VIS markers had been well recognized visually on cone-beam CT in all cases.
Evaluation of Images
The degree of recognition of the prostatic outline despite artifacts on CT was scored as follows: 1, poor; 2, slightly poor; 3, neutral; 4, marginally good; and 5, excellent. The degree of recognition of the marker itself on the prostate on MRI was scored as follows:
1, poor; 2, slightly poor; 3, neutral; 4, marginally good; and 5, excellent. The degree of recognition of the marker and the prostatic outline on MRI was analyzed, and we adopted the best sequences among T2-WI, T2*2D-WI, and T2*3D-WI. Urologists also 
Results
We did not conduct any statistical analyses in this study of five patients. We en-coun-
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tered no difficulties during pelvis plain radiography using either the GA or VIS ( Figure   2 ). On CT, the GA produced moderately bigger artifacts than did the VIS, but the GA did not influence the visualization of the prostate or surrounding organs ( Figure 3 ).
However, the visibility on MRI was clearly better when using the GA than when using the VIS (Figure 4) . The GA had a visibility similar to that of coarse calcification ( Figure 5 ). In contrast, the VIS (0.35 mm) was slightly difficult to visualize on MRI.
Nevertheless, both markers could be recognized equally well on transrectal echography.
Discussion
The clinical results of radiotherapy depend on the reproducibility of high-precision techniques such as IMRT throughout the radiotherapy course, because we monitor the dynamics and increase the dosage to the prostate or reduce the dosage to the surrounding normal tissues based on these findings. In addition, real-time tracking can reduce are most frequently used in Japan. The recognition precision on MRI increases with marker size, thereby simplifying the treatment. However, the recognition precision on CT decreases with increasing marker size, as artifacts begin to appear when a large volume of metal is present. In addition, the prostate is a small organ, and the presence of metal either in the marker or within the organ itself may influence the dose distribution. Tanaka et al. developed an optimal MRI sequence based on marker size, and a marker diameter of 0.35 mm has since been adopted at our hospital [4] [5] .
In February 2016, however, a marker with a diameter of 0.28 mm, a 22 G needle, and iron-containing markers became available in Japan. The GA used in the present study contains 0.5% iron, and its visibility on MRI is reported to be superior to that of noniron-containing markers. Iron-containing markers have been widely used in other countries since 2010, and previous studies have reported fewer artifacts on CT and increased visibility on MRI when using these markers than when using the con-ven-tional gold markers.
Most facilities use 0.35-to 0.75-mm-diameter markers, but recently, by virtue of repeated experience, the 0.5-mm-diametermarker has been preferred. We employed a 0.35-mm marker because it was well recognized on cone-beam CT and helped reduce the artifacts on CT. To our knowledge, no previous studies have compared the outcomes of the GA with those of other markers in the same individual, albeit we did find some reports of phantom studies [5] .
At present only 19 G needles can be sold in Japan, and 22 G needles for VIS are still not available. Nevertheless, in this initial experience of five cases, the chalybeate marker greatly contributed to registration using MRI for radiation treatment planning in clinical practice.
Conclusion
Our findings show that an iron-containing marker is extremely useful in image registration. Bleeding and pain can be avoided by using a thin needle, and the marker can be recognized on prostatic MRI even when using a thin 22 G needle. The present findings suggest that the Gold Anchor will indeed be useful in daily practice.
